We estimated the prevalence and prognostic significance of neuroendocrine (NE) cells in a series of 208 resection specimens containing gastroesophageal junction (GEJ) adenocarcinomas, with 56 specimens containing Barrett’s mucosa. Immunohistochemically, chromogranin A (CGA) was positive in 49% (102/208) of GEJ adenocarcinomas and in 68% (38/56) of Barrett’s mucosas. CGA in GEJ tumors correlated with pTNM stage. CGA in Barrett correlated with pTNM stage and tumor grade of the adjacent carcinoma. Patients with CGA in Barrett had better survival than patients without CGA in Barrett, with 5-year survival percentages of 56% and 9%, respectively. In multivariate analysis, CGA in Barrett was an independent prognostic factor for survival after surgery. Therefore CGA in Barrett adjacent to GEJ adenocarcinoma might be helpful in the assessment of patient outcome.
Hill P, Garbaczewski L, Koppeschaar H, Thijssen JH, de Waard F, Wynder EL. Peptide and steroid hormones in subjects at different risk for diet-related diseases. Am J Clin Nutr48:782-7861988
2.
Iacangelo AL, Eiden LE. Chromogranin A. Current status as a precursor for bloactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept58:65-881995
3.
Winkler H, Fischer-Colbrie R. The chromogranins A and B: The first 25 years and future perspectives. Neuroscience49:497-5281992
4.
Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an “on/off “ switch controlling dense-core secretory granule biogenesis. Cell106:499-5092001
5.
Lloyd RV, Wilson BS. Specific endocrine tissue marker defied by a monoclonal antibody. Science222:628-6301983
6.
Chejfec G, Falkmer S, Askensten U, Grimelius L, Gould VE. Neuroendocrine tumors of the gastrointestinal tract. Pathol Res Pract183:143-1541988
7.
Wilson BS, Lloyd RV. Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Am J Pathol115:458-4681984
8.
Ulich TR, Cheng L, Glover H, Yang K, Lewin KJ. A colonic adenocarcinoma with argentaffin cells. An immunoperoxidase study demonstrating the presence of numerous neuroendocrine products. Cancer51:1483-14891983
9.
Arends JW, Wiggers T, Verstijnen K, Bosman FT. The occurrence and clinicopathological significance of serotonin immunoreactive cells in large bowel carcinoma. J Pathol149:97-1021986
10.
Hamada Y, Oishi A, Shoji T, Takada K, Yamamura M, Hioki K, Yamamoto M. Endocrine cells and prognosis in patients with colorectal carcinoma. Cancer69:2641-26461992
11.
de Bruine AP, Wiggers T, Beek C, Volovics A, von Meyenfeldt M, Arends JW, Bosman FT. Endocrine cells in colorectal adenocarcinomas: Incidence, hormone profile, and prognostic relevance. Int J Cancer54:765-7711993
12.
Grabowski P, Schindler I, Anagnostopoulos I, Foss HD, Riecken EO, Mansmann U, Stein H, Berger G, Buhr HJ, Scherubl H. Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer. Eur J Gastroenterol Hepatol13:405-4112001
13.
Swatek J, Chibowski D. Endocrine cells in colorectal carcinomas. Immunohistochemical study. Pol J Pathol51:127-1362000
14.
Smith DM Jr, Haggitt RC. The prevalence and prognostic significance of argyrophil cells in colorectal carcinomas. Amj Surg Pathol8:123-1281984
15.
Foley EF, Gaffey MJ, Frierson HF Jr. The frequency and clinical significance of neuroendocrine cells within stage III adenocarcinomas of the colon. Arch Pathol Lab Med122:912-9141998
16.
Secco GB, Campora E, Fardelli R, Lapertosa G, De Lucchi F, Gianquinto D, Bonfante P. Chromogranin-A expression in neoplastic neuroendocrine cells and prognosis in colorectal cancer. Tumori82:390-3931996
17.
Mori M, Mimori K, Kamakura T, Adachi Y, Ikeda Y, Sugimachi K. Chromogranin-positive cells in colorectal carcinoma and transitional mucosa. J Clin Pathol48:754-7581995
18.
Pagani A, Papotti M, Abbona GC, Bussolati G. Chromogranin gene expressions in colorectal adenocarcinomas. Mod Pathol8:626-6321995
19.
Ferrero S, Buffa R, Pruneri G, Siccardi AG, Pelagi M, Lee AK, Coggi G, Bosari S. The prevalence and chnical significance of chromogranin A and secretogranin II immunoreactivity in colorectal adenocarcinomas. Virchows Arch426:587-5921995
20.
Park JG, Choe GY, Helman LJ, Gazdar AF, Yang HK, Kim JP, Park SH, Kim YI. Chromogranin-A expression in gastric and colon cancer tissues. Int J Cancer51:189-1941992
21.
Indinnimeo M, Cicchini C, Memeo L, Stazi A, Provenza C, Ricci F, Mingazzini PL. Correlation between chromogranin-A expression and pathological variables in human colon carcinoma. Anticancer Res22:395-3982002
22.
Yao GY, Zhou JL, Lai MD, Chen XQ, Chen PH. Neuroendocrine markers in adenocarcinomas: An investigation of 356 cases. World J Gastroenterol9:858-8612003
23.
Hamilton K, Chiappori A, Olson S, Sawyers J, Johnson D, Washington K. Prevalence and prognostic significance of neuroendocrine cells in esophageal adenocarcinoma. Mod Pathol13:475-4812000
24.
Spechler SJ, Goyal RK. Barrett’s esophagus. N Engl J Med315:362-3711986
25.
Shia J, Tickoo SK, Guillem JG, Qin J, Nissan A, Hoos A, Stojadinovic A, Ruo L, Wong WD, Paty PB, Weiser MR, Minsky BD, Klimstra DS. Increased endocrine cells in treated rectal adenocarcinomas: A possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy. Am J Surg Pathol26:863-8722002
26.
Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg86:529-5351999
27.
Ruol A, Parenti A, Zaninotto G, Merigliano S, Costantini M, Cagol M, Alfieri R, Bonavina L, Peracchia A, Ancona E. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer88:2520-25282000
28.
Tezel E, Nagasaka T, Nomoto S, Sugimoto H, Nakao A. Neuroendocrine-like differentiation in patients with pancreatic carcinoma. Cancer89:2230-22362000
29.
Schleusener JT, Tazelaar HD, Jung SH, Cha SS, Cera PJ, Myers JL, Creagan ET, Goldberg RM, Marschke RF Jr. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer77:1284-12911996
30.
Griffin M, Sweeney EC. The relationship of endocrine cells, dysplasia and carcinoembryonic antigen in Barrett’s mucosa to adenocarcinoma of the oesophagus. Histopathology11:53-621987
31.
Rindi G, Bishop AE, Daly MJ, Isaacs P, Lee FI, Polak JM. A mixed pattern of endocrine cells in meta-plastic Barrett’s oesophagus. Evidence that the epithelium derives from a pluripotential stem cell. Histochemistry87:377-3831987
32.
Buchan AM, Grant S, Freeman HJ. Regulatory peptides in Barrett’s oesophagus. J Pathol146:227-2341985
33.
Jaskiewicz K, Louw J, Anichkov N. Barrett’s oesophagus: Mucin composition, neuroendocrine cells, p53 protein, cellular proliferation and differentiation. Anticancer Res14:1907-19121994
34.
Feurle GE, Helmstaedter V, Buehring A, Bettendorf U, Eckardt VF. Distinct immunohistochemical findings in columnar epithelium of esophageal inlet patch and of Barrett’s esophagus. Dig Dis Sci35:86-921990
35.
Kirkland SC. Clonal origin of columnar, mucous, and endocrine cell lineages in human colorectal epithelium. Cancer61:1359-13631988
36.
de Bruine AP, Dinjens WN, Pijls MM, vd Linden EP, Rousch MJ, Moerkerk PT, de Goeij AF, Bosman FT. NCI-H716 cells as a model for endocrine differentiation in colorectal cancer. Virchows Arch B Cell Pathol Incl Mol Pathol62:311-3201992
37.
Sanduleanu S, De Bruine A, Stridsberg M, Jonkers D, Biemond I, Hameeteman W, Lundqvist G, Stock-brugger RW. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest31:802-8112001
38.
Colombo B, Curnis F, Foglieni C, Monno A, Arrigoni G, Corti A. Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. Cancer Res62:941-9462002
39.
Haggitt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epitheliumlined (Barrett’s) esophagus. Am J Clin Pathol70:1-51978
